<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060294</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000301591</org_study_id>
    <secondary_id>UCLA-0202063</secondary_id>
    <secondary_id>IDEC-UCLA-0202063</secondary_id>
    <nct_id>NCT00060294</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>Phase I Study of Zevalin (90Y-Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can&#xD;
      locate cancer cells and either kill them or deliver radioactive cancer-killing substances to&#xD;
      them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 ibritumomab tiuxetan in&#xD;
      treating patients who have Waldenstrom's macroglobulinemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of yttrium Y 90 ibritumomab tiuxetan in patients&#xD;
           with Waldenstrom's macroglobulinemia.&#xD;
&#xD;
        -  Determine, preliminarily, the response of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of yttrium Y 90 ibritumomab tiuxetan&#xD;
      (IDEC-Y2B8).&#xD;
&#xD;
      Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10&#xD;
      minutes on day 1. Patients then undergo gamma camera scans within 2-24 hours. Approximately&#xD;
      7-14 days after IDEC-In2B8, patients receive rituximab IV and IDEC-Y2B8 IV over 10 minutes.&#xD;
      Treatment with IDEC-Y2B8 may repeat every 12 weeks in the absence of unacceptable toxicity or&#xD;
      the achievement of a maximum cumulative dose.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of IDEC-Y2B8 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no accrual&#xD;
  </why_stopped>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of Waldenstrom's macroglobulinemia confirmed by IgM gammopathy and bone&#xD;
             marrow biopsy&#xD;
&#xD;
               -  Presence of lymphoplasmacytic cells&#xD;
&#xD;
               -  CD20+ plasma cell dyscrasia on the majority of malignant cells&#xD;
&#xD;
               -  Bone marrow involvement of 20-50% by core needle biopsy of at least 1.5 cm in&#xD;
                  length&#xD;
&#xD;
          -  Clinical indication for initiation of treatment, including 1 or more of the following&#xD;
             characteristics:&#xD;
&#xD;
               -  Symptoms associated with the disease (e.g., fatigue, asthenia, or painful&#xD;
                  adenopathy)&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  IgM greater than 3 g/L&#xD;
&#xD;
               -  Progression as indicated by a rate of IgM rise of more than 0.5 g over 6 months&#xD;
&#xD;
          -  No myelodysplastic syndromes or profound hypocellularity of the bone marrow&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Total B-lymphocyte count less than 5,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No hyperviscosity syndrome&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 year after study&#xD;
             completion&#xD;
&#xD;
          -  No uncontrolled CNS disease&#xD;
&#xD;
          -  No serious nonmalignant disease that would preclude study participation&#xD;
&#xD;
          -  No other concurrent active malignancy except controlled skin cancer or prostate cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  More than 4 months since prior rituximab&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior high-dose chemotherapy (unless patient has had prior back-up stem cell&#xD;
             collections)&#xD;
&#xD;
          -  More than 6 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

